Navigation Links
Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
Date:7/30/2013

SAN FRANCISCO, July 30, 2013 /PRNewswire/-- Nektar Therapeutics (NASDAQ: NKTR) today announced that enrollment is complete in the pivotal clinical study of etirinotecan pegol (NKTR-102) in patients with metastatic breast cancer.  The Phase 3 study, also known as the BEACON trial, is evaluating etirinotecan pegol versus a single-agent treatment of physician's choice for the treatment of locally recurrent or metastatic breast cancer.  Etirinotecan pegol is the first long-acting topoisomerase I inhibitor designed to concentrate in tumor tissue to provide sustained tumor suppression throughout the entire chemotherapy cycle."Strong interest in etirinotecan pegol and the BEACON study from investigators and patients has allowed us to rapidly complete our recruitment and enrollment," said Robert Medve, MD, Senior Vice President and Chief Medical Officer of Nektar Therapeutics. "We recognize the high unmet need for new treatment options in the metastatic breast cancer setting, particularly among patients with HER2-negative breast cancer whose disease has progressed following anthracycline, taxane and capecitabine therapies. The primary endpoint in the BEACON study is survival and as we have previously announced, we plan to conduct an interim futility analysis for the BEACON study in the first quarter of next year with topline survival data to be available around the end of 2014."

Positive Phase 2 data for etirinotecan pegol was previously announced and presented at the ASCO 2011 Breast Cancer Symposium (Garcia et. al., ASCO 2011).  Etirinotecan pegol achieved a confirmed objective response rate by RECIST of 29 percent. In addition, 71 percent of patients in the study had no tumor progression, defined as complete response (CR), partial response (PR) and stable disease (SD), as measured by RECIST criteria.
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
2. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
3. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
4. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City
5. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
6. Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
7. Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
9. Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
10. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
11. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) ... focus on Omega-3 therapies for cardiovascular disease (CVD) ... financial results for the fiscal year ended December ... in Canadian dollars unless otherwise stated. ... the right strategic partners and additional capitalization in ...
(Date:4/30/2015)... , April 30, 2015  Accuray Incorporated ... has signed an agreement with MIM Software Inc. ... TomoTherapy ® and CyberKnife ® product portfolios. ... and MIM technology. This is Accuray,s second collaboration ... development of the first iPad-based treatment plan review ...
(Date:4/30/2015)... , April 30, 2015  Thoratec Corporation (NASDAQ: ... support therapies to save, support and restore failing hearts, ... America Merrill Lynch 2015 Healthcare Conference on Thursday, May ... and Chief Executive Officer, will provide an update on ... (1:40 p.m., Eastern Daylight Time). The presentation ...
Breaking Medicine Technology:Pivotal Therapeutics Announces 2014 Financial Results 2Pivotal Therapeutics Announces 2014 Financial Results 3Pivotal Therapeutics Announces 2014 Financial Results 4Pivotal Therapeutics Announces 2014 Financial Results 5Pivotal Therapeutics Announces 2014 Financial Results 6Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 2Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 3Thoratec Presentation At Bank Of America Merrill Lynch Healthcare Conference To Be Webcast 2
... WELLINGTON , Fla., May 10 Dr. ... children with newly diagnosed type 1 diabetes for Protege Encore, ... second of two Phase III studies testing the safety and ... known as Protege, has completed enrollment of more than 530 ...
... Ireland , May 10 Warner Chilcott plc ... of America Merrill Lynch Healthcare Conference on Tuesday, May 11, 2010 ... be Paul Herendeen , Executive Vice President and Chief Financial Officer. , ... Warner Chilcott ,s presentation will be ...
Cached Medicine Technology:Protege Encore Clinical Trial Evaluates New Investigational Approach For Individuals Recently Diagnosed With Type 1 Diabetes 2
(Date:5/3/2015)... “ BolehVPN ” was featured on NewsWatch as part of ... technology products available to consumers. Scott Steinberg, a technology expert ... with viewers how to protect their private information. , A ... and even more so online. It helps everyone stay connected ... world. In terms of work, the internet makes things more ...
(Date:5/3/2015)... Mateo, CA (PRWEB) May 03, 2015 ... service, MnemeTherapy® at two upcoming area seminars. The first ... the PSA Annual Regional Stroke Conference to be held ... be offered on Wednesday, May 13 during the Dementia ... Plaza. , “These seminars offer an excellent opportunity ...
(Date:5/3/2015)... It is not too late to register to take ... of Lissa Anne Been in Arnold, Missouri on May 9, ... to honor her loving memory. It has benefited the renowned Brain ... turned 37, Lissa suffered a brain aneurysm . After two ... This event is designed to serve as a remembrance of her ...
(Date:5/2/2015)... As one of only 30 Illinois companies to ... Achievement and Recognition Program (SHARP) certification, Essentra Specialty ... Illinois Department of Labor to host this special event. ... by the Occupational Safety and Health Administration’s (“OSHA”) Onsite ... meet or exceed all of the necessary regulations and ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 Vancouver fencing company, ... now provide valuable advice to prospective clients related to their ... looking to install railings around their decks and patios. While ... questions that pop up once the person rolls up their ... of installing a railing in finding a gate that matches ...
Breaking Medicine News(10 mins):Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2
... & Full Year 2008 Earnings Conference Call , Thursday, February 12, ... Jan. 12 Cephalon, Inc . (Nasdaq: CEPH ... quarter and full year 2008 results for 5:00 p.m. EST on ... 4:10 p.m. EST Q4 & FY 2008 ...
... a sagging economy? Not necessarily the quick fix that you ... plastic surgeons.Recently, the U.S. Food and Drug Administration (FDA) gathered ... the use of dermal fillers. Although the injections have been ... (the creases running from the nose to the corners of ...
... Beginning Thursday, January 15, 2009, cosmetic surgeons from around ... Cosmetic Surgery,s 25th Anniversary Scientific Meeting to share and ... A Day Over Twenty-five" will be held from January ... Ridge Resort and Spa in Phoenix, Arizona.AACS continues its ...
... to study inherited susceptibility for skin cancer in mice. In the process, ... role in controlling this susceptibility. The technique, the scientists say, could ... ... January 12, 2009 -- UCSF researchers have used a new ...
... Steve Shulman to BoardHOUSTON, Jan. 12 Access ... of outsourced medical implantable device management solutions to ... board of directors has appointed board member Steve ... appointment following its second consecutive year of revenue ...
... of minimally invasive surgery procedures in operating theatres. However, ... much to be desired. Researcher Magdalena Chmarra has changed ... system which records and analyses the surgeon,s movements. As ... an objective benchmark for measuring a surgeon,s basic skills ...
Cached Medicine News:Health News:Dr. Sherrell Aston Addresses the Popularity of Dermal Fillers and Possible Long Term Side Effects 2Health News:The State of the Cosmetic Surgery Industry is Discussed at AACS 25th Anniversary Scientific Meeting 2Health News:UCSF Researchers Use New Tools to Move in on Cancer Susceptibility Genes 2Health News:UCSF Researchers Use New Tools to Move in on Cancer Susceptibility Genes 3Health News:UCSF Researchers Use New Tools to Move in on Cancer Susceptibility Genes 4Health News:Access MediQuip Appoints Former Priority Healthcare CEO to Chairman of the Board 2Health News:Access MediQuip Appoints Former Priority Healthcare CEO to Chairman of the Board 3Health News:New training method helps surgeons evaluate their own minimally invasive surgery skills 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: